Institute for Cancer Research


Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.

The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.

Gunnar Sæter<br>Scientific director
Gunnar Sæter
Scientific director

Scientific production - Institute for Cancer Research

  Publications Doctoral theses
2015 so far  
2014 176  
2013 197 27
2012 175 18
2011 201 22
2010 221 11
2009 182 21
2008 152 11

Annual report 2014 (pdf format)


Latest news

Llorente and coworkers report promising prostate cancer biomarkers in urinary exosomes

First author Anders Øverby (left) and Alicia Llorente
First author Anders Øverby (left) and Alicia Llorente

Alicia Llorente and coworkers from the Department of Molecular Cell Biology at the Institute for Cancer Research recently published in Oncotarget detailed mass spectrometry analyses of exosomes purified from urine of 16 prostate cancer patients and 15 healthy volunteers that revealed upregulation of 221 proteins in the patient samples. At 100% specificity, 17 of these proteins displayed individual sensitivities between 60 and 94%. Combination of two of the upregulated proteins (TM256 and LAMTOR1) resulted in 100% specificity and 100% sensitivity for these samples.


Microscopy infrastructure funded by the Norwegian Research Council


The Norwegian Advanced Light Microscopy Imaging Network, NALMIN, coordinated by Harald Stenmark at Institute for Cancer Research and Centre for Cancer Biomedicine, has been funded by 49.5 MNOK by the Research Council of Norway. This is good news for Norwegian researchers who use light microscopy in their studies.


Cover article on personalized cancer medicine and big data in META

Johannessen (left) and Skotheim
Johannessen (left) and Skotheim

Bjarne Johannessen and Rolf Skotheim from the Department of Molecular Oncology at the Institute for Cancer Research have written about bioinformatics and big data challenges in cancer genomics. The popularized science article appeared as a cover story in the META magazine:

The META journal is published by UNINETT Sigma2, and the aim is to present research projects that are part of Notur and Norstore.


Innovation prize to Erik Fosse

Erik Fosse
Erik Fosse

Professor Erik Fosse from The Intervention Centre at the Division of Diagnostics and Intervention, OUS, is awarded the University of Oslo Innovation prize for his creations within the fields of medicine and health service.
Fosse will receive the prize at a seremony taking place during the annual party for the University of Oslo September 2nd.


Paper from OUS/CCB researchers dedicated commentary articles in both Nature and Science

Figure from the Nature paper
Figure from the Nature paper

A recent Nature paper by Marina Vietri and colleagues in Harald Stenmark's group at Institute for Cancer Research and Centre for Cancer Biomedicine has attracted considerable attention worldwide.

This paper, which shows a mechanism for nuclear envelope sealing during mitotic exit and its importance for genome integrity, has been dedicated commentary articles in both of the world's most influential scientific journals, Nature and Science. This is very unusual for cell biological papers and illustrates the impact of the findings by the Norwegian research group.


OUS research blog June 16th:

What is the cost of a cancer patient's life?

Tine N. Alver
Tine N. Alver

In an article for the OUS research blog published June 16th PhD student Tine Norman Alver from the Department of Tumor Biology at the Insitute for Cancer researchs discusses dilemmas and viewpoints around cost and payment of expensive cancer medicines and treatments, illustrated by some concrete recent cases from Norway. Her blog article (in Norwegian) is entitled "What is the cost of a cancer patient's life".